Our portfolio is composed of a wide range of chemical synthesis generics and high-tech biosimilars -such as cytokines, monoclonal antibodies, fusion proteins and recombinant vaccines- for the prevention and treatment of autoimmune and chronic-degenerative diseases, hematological and metabolic disorders, as well as malignant neoplasms, among other conditions.